Journals / Erciyes Tıp Dergisi / 2012 / Cilt: 34 - Sayı: 3

Deneysel kontrollü non-heart beating donor modelinde edaravonun karaciğer hasarını önleyici etkisi

The effect of edaravone on liver damage in controlled experimental non-heart-beating donor model

Pages
127–131
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: It was found that the Edaravone Groups have lower levels of AST, ALT, IL-6, and TNF-α and have higher levels of IL-10, PCNA labeling index, and Bcl-2 staining index when compared to Control Groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to investigate the effect of Edaravone on viability of hepatocytes in experimental controlled non-heart beating donor models of rats and additionaly to determine the usefullness of these grafts.
📊
Key Findings & Data:Material and Methods: Forty Wistar-Albino male rats, 225- 290 grams in weight were randomly assigned to five different groups (sham, two control and two study groups).
💡
Conclusion & Impact:Results: It was found that the Edaravone Groups have lower levels of AST, ALT, IL-6, and TNF-α and have higher levels of IL-10, PCNA labeling index, and Bcl-2 staining index when compared to Control Groups.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to investigate the effect of Edaravone on viability of hepatocytes in experimental controlled non-heart beating donor models of rats and additionaly to determine the usefullness of these grafts. Material and Methods: Forty Wistar-Albino male rats, 225- 290 grams in weight were randomly assigned to five different groups (sham, two control and two study groups). Cardiac arrest was performed by intracardiac KCl injection (0.2 mL). Livers were subjected to 30 minutes of warm ischemia and were washed out with 50 mL Euro Collins solution via a portal vein catheter after total hepatectomy. Liver grafts in the control groups and the study groups were perfused with Histidin- Tryptophan- Ketoglutarat solution including SF and edaravone (1 mg/kg), respectively. The perfusion was lasted for 30 or 60 min using a circulatory system. AST, ALT, IL-10, IL-6, TNF-α levels were measured in the perfusion fluids. The grafts were saved under suitable conditions for histopathological assessment. Results: It was found that the Edaravone Groups have lower levels of AST, ALT, IL-6, and TNF-α and have higher levels of IL-10, PCNA labeling index, and Bcl-2 staining index when compared to Control Groups. Conclusion: Edaravone increases the viability of hepatocytes biochemically, morphologically in experimental controlled non-heart beating donor models of rats.

Özet

Amaç: Sıçanlarda deneysel kontrollü kalp atımı olmayan (nonheart beating) donör modelinde, Edaravonun karaciğer hücre canlılığına etkisini ve kullanılabilirliliğini araştırmak amaçlandı. Gereç ve Yöntemler: Ağırlığı 225-290 gram arasında olan, 40 adet Wistar-Albino erkek sıçanlar rastlantısal olarak 5 gruba (sham, iki kontrol ve iki çalışma grubu) ayrıldı. Kalp içine uygulanan KCl enjeksiyonu (0,2 mL) ile kalp durduruldu. Karaciğerler otuz dakika süreyle sıcak iskemiye maruz bırakıldı ve total hepatektomiden sonra portal ven kataterize edilerek 50 mL Euro Collins solüsyonu ile olarak yıkandı. Kontrol ve çalışma grubundaki karaciğerler, SF veya edaravon (1mg/kg) içeren Histidin- Triptofan- Ketoglutarat solüsyonu ile perfüze edildi. Perfüzyon bir sirkülatuar sistem kullanılarak 30 dakika veya 60 dakika sürdürüldü. AST, ALT, IL-6, IL-10, TNF-α ölçümleri perfüzyon sıvılarında yapıldı. Histokimyasal çalışmaları için de karaciğerler uygun koşullarda saklandı. Bulgular: Edaravon verilen gruplarda, kontrol gruplarına göre AST, ALT, IL-6 ve TNF-α değerleri, daha düşük, IL-10 değerleri, PCNA işaretleme oranları ve Bcl-2 boyanma yüzdeleri ise daha yüksek bulundu. Sonuç: Edaravon; deneysel kontrollü non-heart beating donör modelinde hepatosit canlılığını, biyokimyasal ve morfolojik açıdan artırmaktadır.

🔖

Cite This Article

YILMAZ, Z., SARAYMEN, R., ÇETİN, M. M., DENİZ, K., ARTIŞ, T. (2022). Deneysel kontrollü non-heart beating donor modelinde edaravonun karaciğer hasarını önleyici etkisi. Erciyes Tıp Dergisi, Cilt: 34 - Sayı: 3, 127–131. https://ajindex.com/articles/502441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Titiz İ, Aker F, Arman A, ve ark. Renal Transplasyona Pratik Yaklaşım, 2. Baskı, İstanbul: ISBN:975-93649-0-5 (Eczacıbaşı İlac Pazarlama’nın katkılarıyla); 2004. s.7-8
  2. D’alessandro AM, Hoffmann RM, Knechtle SJ, Odorico JS, Becker YT, Musat A, et al. Liver transplantation from controlled non-heart beating donors. Surgery 2000; 128(4): 579-88
  3. Marcos A. Right lobe living donor liver transplantation: a review. Liver Transpl 2000; 6(1): 3-20
  4. Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, Yamamoto E, et al. Living related liver transplantation in children. Am J Surg 1994; 168(1): 41-8
  5. Busuttil RW, Goss JA. Split liver transplantation. Ann Surg 1999; 299(3): 313-21
  6. Becker YT. Use of marginal donors in kidney transplantation. Graft 2000; 3: 216-20
  7. D’Alessandro AM, Hoffmann RM, Knechtle SJ, Eckhoff DE, Love RB, Kalayoglu M, et al. Controlled non-heart-beating donors: a potential source of extrarenal organs. Transplant Proc 1995; 27(1): 707-9
  8. Nicholson M. Kidney transplantation from asystolic donors. Br J Hosp Med 1996; 55(1-2): 51-6
  9. Otero A, Gómez-Gutiérrez M, Suárez F, Arnal F, Fernández-García A, Aguirrezabalaga J, et al. Liver transplantation from Maastricht category 2 non-heart-beating donors: a source to increase the donor pool? Transplant Proc 2004; 36(3): 747-50
  10. Nakamura A, Akamatsu Y, Miyagi S, Fukumori T, Sekiguchi S, Satomi S. A free radical scavenger, edaravone, prevents ischemia-reperfusion injury in liver grafts from non-heart-beating donors. Transplantation Proeedings 2008; 40(7): 2171-4
  11. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaraovene (3-Methyl- 1-Phenyl-2-Pyrazolin-5-One), A Novel free radical scavenger, for treatment of cardiovasculer diseases. Recent Pat Cardiovasc Drug Discov 2006; 1(1): 85-93
  12. Bourdi M, Mascbuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35(2): 289-98
  13. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998; 28(6): 1597-606
  14. Louis H, Van Leathem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis inuced by carbon tetrachloride in mice. Hepatology 1998; 28(6): 1607-15